Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Apr 13;16(1):148.
doi: 10.1186/s12936-017-1797-9.

The end of a dogma: the safety of doxycycline use in young children for malaria treatment

Tiphaine Gaillard  1 , Sébastien Briolant  2   3 , Marylin Madamet  2   3   4 , Bruno Pradines  5   6   7
Affiliations
Review

The end of a dogma: the safety of doxycycline use in young children for malaria treatment

Tiphaine Gaillard et al. Malar J. .

Abstract

Anti-malarial drug resistance to chloroquine and sulfadoxine-pyrimethamine has spread from Southeast Asia to Africa. Furthermore, the recent emergence of resistance to artemisinin-based combination therapy (ACT) in Southeast Asia highlights the need to identify new anti-malarial drugs. Doxycycline is recommended for malaria chemoprophylaxis for travel in endemic areas, or in combination with the use of quinine for malaria treatment when ACT is unavailable or when the treatment of severe malaria with artesunate fails. However, doxycycline is not used in young children under 8 years of age due to its contraindication due to the risk of yellow tooth discolouration and dental enamel hypoplasia. Doxycycline was developed after tetracycline and was labelled with the same side-effects as the earlier tetracyclines. However, recent studies report little or no effects of doxycycline on tooth staining or dental enamel hypoplasia in children under 8 years of age. In the United States, the Centers for Disease Control and Prevention have recommended the use of doxycycline for the treatment of acute and chronic Q fever and tick-borne rickettsial diseases in young children. It is time to rehabilitate doxycycline and to recommend it for malaria treatment in children under 8 years of age.

Keywords: Anti-malarial drug; Antibiotics; Children; Doxycycline; Malaria; Plasmodium falciparum; Prophylaxis; Resistance; Treatment.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

  • Ticks and Tick-Borne Diseases in Central America and the Caribbean: A One Health Perspective.
    Charles RA, Bermúdez S, Banović P, Alvarez DO, Díaz-Sánchez AA, Corona-González B, Etter EMC, Rodríguez González I, Ghafar A, Jabbar A, Moutailler S, Cabezas-Cruz A. Charles RA, et al. Pathogens. 2021 Oct 2;10(10):1273. doi: 10.3390/pathogens10101273. Pathogens. 2021. PMID: 34684222 Free PMC article. Review.
  • Alternative treatment strategies to accelerate the elimination of onchocerciasis.
    Boussinesq M, Fobi G, Kuesel AC. Boussinesq M, et al. Int Health. 2018 Mar 1;10(suppl_1):i40-i48. doi: 10.1093/inthealth/ihx054. Int Health. 2018. PMID: 29471342 Free PMC article.
  • Intravenous Doxycycline, Azithromycin, or Both for Severe Scrub Typhus.
    Varghese GM, Dayanand D, Gunasekaran K, Kundu D, Wyawahare M, Sharma N, Chaudhry D, Mahajan SK, Saravu K, Aruldhas BW, Mathew BS, Nair RG, Newbigging N, Mathew A, Abhilash KPP, Biswal M, Prasad AH, Zachariah A, Iyadurai R, Hansdak SG, Sathyendra S, Sudarsanam TD, Prakash JAJ, Manesh A, Mohan A, Tarning J, Blacksell SD, Peerawaranun P, Waithira N, Mukaka M, Cheah PY, Peter JV, Abraham OC, Day NPJ; INTREST Trial Investigators. Varghese GM, et al. N Engl J Med. 2023 Mar 2;388(9):792-803. doi: 10.1056/NEJMoa2208449. N Engl J Med. 2023. PMID: 36856615 Free PMC article. Clinical Trial.
  • Potential Prophylactic Treatments for COVID-19.
    Ben-Zuk N, Dechtman ID, Henn I, Weiss L, Afriat A, Krasner E, Gal Y. Ben-Zuk N, et al. Viruses. 2021 Jul 2;13(7):1292. doi: 10.3390/v13071292. Viruses. 2021. PMID: 34372498 Free PMC article. Review.
  • Q Fever Osteoarticular Infection in Children.
    Dabaja-Younis H, Meir M, Ilivizki A, Militianu D, Eidelman M, Kassis I, Shachor-Meyouhas Y. Dabaja-Younis H, et al. Emerg Infect Dis. 2020 Sep;26(9):2039-45. doi: 10.3201/eid2609.191360. Emerg Infect Dis. 2020. PMID: 32818415 Free PMC article.
See all "Cited by" articles

References

    1. WHO. World Malaria Report 2016. Geneva: World Health Organization; 2016.
    1. Mita T, Venkatesan M, Ohashi J, Culleton R, Takahashi N, Tsukahara T, et al. Limited geographical origin and global spread of sulfadoxine-resistant dhps alleles in Plasmodium falciparum populations. J Infect Dis. 2011;204:1980–1988. doi: 10.1093/infdis/jir664. - DOI - PMC - PubMed
    1. Wootton JC, Feng X, Ferdig MT, Cooper RA, Mu J, Baruch DI, et al. Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum. Nature. 2002;418:320–323. doi: 10.1038/nature00813. - DOI - PubMed
    1. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455–467. doi: 10.1056/NEJMoa0808859. - DOI - PMC - PubMed
    1. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2015;371:411–423. doi: 10.1056/NEJMoa1314981. - DOI - PMC - PubMed